Question-and-Answer Session
Operator
Thank you sir, ladies and gentlemen at this time we will begin the question and answer session. (Operator Instructions) One moment please for the first question. Our first question will from the line of Richard Smith with J.P. Morgan. Please go ahead.
Richard Smith - J. P. Morgan
Good evening. I just wanted to ask you a question about SGN-33 the Phase Ib study you are enrolling in at the moment with 50 patients. Give us a sense of what the purpose of that study is. Does it allow you to go to development in the younger AML with patients? Can you give us a sense of the reason behind that study?
Clay B. Siegall
Sure Richard, this is Clay. Thank you for the question. We were pleased with our single agent response data in our Phase I dose escalation or Phase I if you will, Phase Ia dose escalation study and we wanted to understand a little bit more about the single agent activity and before we made any formal considerations to go forward on a potential registration track as a single agent. We already had decided to go forward into a large Phase IIb study at a combination agent, so we wanted more information as a single agent then and information at the dose we are taking to the Phase I to Phase II which is the 8mg per kilogram dose level which we are using in Phase Ib. In the Phase IIb study we are using a flat dosing which represents closely, it closely approximates 8 milligrams per kilogram so that we can roughly talk about that dose. Tom, do you want to add anything more? Tom Reynolds, our CMO.
Thomas C. Reynolds
Yes Clay, the only other comment was that the Ib study is also an older AML and MDS so it is really targeting that older population and really trying to clarify whether the response rate that we are seeing is... How we see that looks with more patients, better idea of the tolerability profile and whether it will help us move forward with the drug not only with the elderly population but also to understand how it might apply to the younger population.
Richard Smith - J. P. Morgan
Is there any plan to younger patients?
Thomas C. Reynolds
Yes, we are actively working on plans for how to bring this drug forward into younger AML. We think there are chances to use this both in combination with chemotherapy and also the post transplant setting. I think later on in this year as we continue to develop our plan and see some more data from the Phase I, we will be able to articulate that and give you more visibility into that so stay tuned.
- To read the full transcript on Seeking Alpha, click here »
